Closed Incision Disposable Negative Pressure Wound Therapy in Immediate Postmastectomy Breast Reconstruction

March 21, 2021 updated by: Karolina Pieszko, University in Zielona Góra

Experience and Comparison Between Closed Incision Disposable Negative Pressure Wound Therapy With Standard Care in Immediate Postmastectomy Breast Reconstruction - Prospective, Randomized and Controlled Study

The study aimed to assess the impact of the use of closed incision negative pressure wound therapy (ciNPWT) after immediate breast reconstruction on the number of surgical-site complications, skin surface temperature, objective elastic and viscoelastic and subjective scar's quality to determine risk factors that could be considered as indications for prophylactic ciNPWT application.

Study Overview

Status

Unknown

Detailed Description

Breast cancer excluding skin cancer is the most commonly diagnosed cancer after lung cancer among women. In recent years, the incidence rate of breast cancer has been rising by 0,3% annually. Screening tests are designed to diagnose breast cancer in possible early stadium of disease. Rapid diagnosis and efficacy of neoadjuvant and adjuvant therapies influence on immediate breast reconstructions after skin (SSM) and nipple-sparing mastectomies (NSM). The prophylactic methods of reducing a higher wound healing complication rate after neoadjuvant and adjuvant therapies are crucial.

The study aimed to assess the impact of the use of closed incision negative pressure wound therapy (ciNPWT) after immediate breast reconstruction on the number of surgical-site complications, skin surface temperature, objective elastic and viscoelastic and subjective scar's quality to determine risk factors that could be considered as indications for prophylactic ciNPWT application.

The analysis included data from anamnesis, details of performed surgical procedure, measurements of skin surface temperature with Skin-Thermometer® probe, measurements of skin elasticity with Cutometer® probe, and scar assessments according to POSAS v2.0 questionnaire for patient and observer.

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Lubuskie
      • Zielona Gora, Lubuskie, Poland, 65-046
        • University in Zielona Gora

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • >= 18 years of age
  • indications for immediate breast reconstruction

Exclusion Criteria:

  • pregnancy or lactation,
  • use of steroids, use of immune modulators known to affect wound healing;
  • tattoos in the area of the incision;
  • breast skin conditions such as cutis laxa;

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: VAC group
A randomized group of patients receiving negative pressure wound therapy dressing (Avelle-ConvaTec) on closed incision
immediate mastectomy with breast reconstruction with implants or expanders
Other Names:
  • immediate mastectomy with breast reconstruction with implants or expanders
Active Comparator: ST group
A randomized group of patients receiving standard dressing (sterile gauze and medical tape) on closed incision
immediate mastectomy with breast reconstruction with implants or expanders
Other Names:
  • immediate mastectomy with breast reconstruction with implants or expanders

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postsurgical complications - reported for 60 patients
Time Frame: 1 month
surgical site complications
1 month
Postsurgical complications - reported for 60 patients
Time Frame: 1 year
surgical site complications
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Superficial Skin Temperature (SST) of scar, skin next to scar and the second breast
Time Frame: 1 week after surgery
measure SST with Skin-Thermometer
1 week after surgery
Superficial Skin Temperature (SST) of scar, skin next to scar and the second breast
Time Frame: 1 month after surgery
measure SST with Skin-Thermometer
1 month after surgery
Objective examination of scar quality
Time Frame: 1 year after surgery
measure skin elasticity with Cutometer
1 year after surgery
Subjective examination of scar quality
Time Frame: 1 year after surgery

POSAS 2.0 (Patient and Observer Scar Assessment Scale) questionnaire for the observer and the patient.

Questions regards painful, itchy scar, difference between scar and normal skin. The min score is 7, the max score is 70. The higher score means better result

1 year after surgery
Subjective quality of life
Time Frame: 1-2 years after surgery
BREAST-Q reconstruction module and Breast implant illness survey for patients. Questions about self-confidence, comfort, acceptance of new appearance, feeling of implants, breast pain. The min score is 1, the max 3-5 depending on part of questionnaire
1-2 years after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Study Chair: Dawid Murawa, PROF, University in Zielona Gora

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2019

Primary Completion (Actual)

January 1, 2019

Study Completion (Anticipated)

July 1, 2021

Study Registration Dates

First Submitted

March 17, 2021

First Submitted That Met QC Criteria

March 17, 2021

First Posted (Actual)

March 22, 2021

Study Record Updates

Last Update Posted (Actual)

March 24, 2021

Last Update Submitted That Met QC Criteria

March 21, 2021

Last Verified

March 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ZG01012019

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on Immediate Breast reconstruction

3
Subscribe